Prosecution Insights
Last updated: July 17, 2026
Application No. 18/229,323

Methods for Treating Eosinophilic Esophagitis

Final Rejection §112
Filed
Aug 02, 2023
Priority
Feb 23, 2018 — provisional 62/634,446 +1 more
Examiner
SITTON, JEHANNE SOUAYA
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Children's Hospital Medical Center
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
354 granted / 669 resolved
-7.1% vs TC avg
Strong +48% interview lift
Without
With
+48.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
46 currently pending
Career history
727
Total Applications
across all art units

Statute-Specific Performance

§101
8.7%
-31.3% vs TC avg
§103
39.8%
-0.2% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 669 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Currently, claims 1-12 are pending in the instant application. All the amendments and arguments have been thoroughly reviewed but are deemed insufficient to place this application in condition for allowance. The following rejection is necessitated by amendment. It constitutes the complete set being presently applied to the instant Application. This action is FINAL. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The rejections under 35 USC 112(a) are withdrawn in view of the amendments to the claims as well as the arguments presented in the response regarding support for the newly added claims in the specification. The rejection under 35 USC 112(b) is withdrawn in view of the amendments to the claims. Claim Objections Claim 1 is objected to because of the following informalities: Claim 1 ends in a semicolon (;), instead of a period (.). Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 6 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Claim 1 is objected to, claim 6 is rejected. Claims 2-5 and 7-12 are objected to for being dependent on a claim that is objected to or rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-0752. The examiner is a hoteling examiner and can normally be reached Mondays-Fridays from 8:00 AM to 2:00 PM Eastern Time Zone. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Winston Shen, can be reached on (571) 272-3157. The fax phone number for organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEHANNE S SITTON/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Aug 02, 2023
Application Filed
Aug 13, 2025
Non-Final Rejection mailed — §112
Feb 13, 2026
Response Filed
May 20, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679872
TRANSMEMBRANE PORE CONSISTING OF TWO CSGG PORES
2y 1m to grant Granted Jul 14, 2026
Patent 12663420
DNAZYMES FOR DETECTING LEGIONELLA PNEUMOPHILA
4y 3m to grant Granted Jun 23, 2026
Patent 12662695
Non-Invasive Gene Mutation Detection in Lung Cancer Patients
3y 9m to grant Granted Jun 23, 2026
Patent 12655468
Genetic Predictors of a Response to Treatment with CRHR1 Antagonists
5y 5m to grant Granted Jun 16, 2026
Patent 12655485
METHOD FOR DIRECT MICROBIAL IDENTIFICATION
3y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
99%
With Interview (+48.1%)
3y 7m (~8m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 669 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month